FDA Scrutiny of Antidepressants & RSV Shots, Antibiotic Production Shifts – Week in Pharma

FDA Scrutiny of Antidepressants & RSV Shots, Antibiotic Production Shifts – Week in Pharma

February 23, 2026 discoverhiddenusacom Health

Recent developments at the U.S. Food and Drug Administration and within the pharmaceutical industry signal potential shifts in drug regulation and antibiotic availability. These changes could have implications for patient care and public health initiatives.

FDA Priorities Under New Leadership

Scrutiny of Medications

Tracy Beth Høeg, the head of the centre for Drug Evaluation and Research, has indicated she will prioritize evaluating the safety of antidepressants used during pregnancy and the monoclonal antibody shots protecting infants against RSV. This focus reflects her past work in these areas. She also expressed interest in bringing her experience with vaccine policy into the drug centre.

Did You Know? Richard Pazdur retired from his longtime role as a regulator due to concerns about the politicization of scientific processes at the FDA.

Leadership Transition

Høeg assumed her position in December, becoming the fifth person to lead the drug centre since the start of 2025. Previously, she took steps to limit access to Covid-19 shots and oversaw vaccine surveillance efforts, taking those responsibilities from career staff.

Antibiotic Production Concerns

Roche’s Decision

Roche is seeking a buyer for Rocephin, a key antibiotic, and plans to cease manufacturing by 2030. This decision is attributed to rising manufacturing costs, falling prices, and increased competition from generic alternatives. Rocephin is used to treat severe bacterial infections like meningitis and pneumonia and is listed as an essential medicine by both the World Health Organization and the European Union.

Expert Insight: The discontinuation of Rocephin production highlights the economic challenges facing antibiotic manufacturers, potentially impacting the availability of essential medications and exacerbating the global issue of antibiotic resistance.

European Response

This move occurs as the European Union aims to reduce its reliance on generic drugs from Asia and encourage production within the bloc, including Switzerland, through the new Critical Medicines Act. Last year, Danish manufacturer Xelia also halted production of several key antibiotic ingredients, indicating a broader trend within the industry.

What Might Happen Next

If Roche finds a buyer for Rocephin, production could continue, potentially mitigating disruptions in supply. However, if a buyer isn’t found, the discontinuation of manufacturing by 2030 could lead to shortages and increased costs for this essential antibiotic. The FDA’s increased scrutiny of antidepressants and RSV shots could result in revised safety guidelines or labeling requirements. It is also possible that vaccine policy will undergo changes under Høeg’s leadership.

Frequently Asked Questions

What medications will the FDA be scrutinizing?

The FDA will be scrutinizing antidepressants taken by pregnant women and the shots used to protect babies from RSV.

Why is Roche stopping production of Rocephin?

Roche is stopping production of Rocephin due to rising manufacturing costs, falling prices, and intensifying generic competition.

What is the European Union doing to address antibiotic production?

The European Union is pushing to reduce reliance on Asian generics and relocate production closer to the bloc, including to Switzerland, under the new Critical Medicines Act.

How might these changes in drug regulation and antibiotic availability affect healthcare access and affordability in the coming years?

,